Evidence map›Paper›PMID 36463214›Full record

Trial reportHarm reduction journal2022

Participant perceptions on the acceptability and feasibility of a telemedicine-based HIV PrEP and buprenorphine/naloxone program embedded within syringe services programs: a qualitative descriptive evaluation.

Amy Corneli, Brian Perry, Andrea Des Marais, Yujung Choi, Hillary Chen, Rebecca Lilly, Denae Ayers, Jesse Bennett, Lauren Kestner, Christina S Meade and 2 more

Registry-linked trialAbstract readClinical Trial
In one paragraph

Trial report in Harm reduction journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04521920 (Providing Comprehensive Harm Reduction Via Telemedicine for PWID Using Syringe Services Programs), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04521920 nacompletednot on this map

Providing Comprehensive Harm Reduction Via Telemedicine for PWID Using Syringe Services Programs: a Feasibility Study

TypeinterventionalSponsorDuke UniversityRan2020 to 2021Enrolled17ConditionsOpioid Use, Opioid-use Disorder, Risk Reduction, HivArmsSuboxone, PrEP
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Amy CorneliDepartment of Population Health Sciences, Duke University School of Medicine, 215 Morris St, Durham, NC, 27701, USA. amy.corneli@duke.edu.
Brian PerryDepartment of Population Health Sciences, Duke University School of Medicine, 215 Morris St, Durham, NC, 27701, USA.
Andrea Des MaraisDepartment of Population Health Sciences, Duke University School of Medicine, 215 Morris St, Durham, NC, 27701, USA.
Yujung ChoiDepartment of Population Health Sciences, Duke University School of Medicine, 215 Morris St, Durham, NC, 27701, USA.
Hillary ChenDepartment of Population Health Sciences, Duke University School of Medicine, 215 Morris St, Durham, NC, 27701, USA.
Rebecca LillyNorth Carolina Harm Reduction Coalition, Wilmington, NC, USA.
Denae AyersQueen City Harm Reduction, Charlotte, NC, USA.
Jesse BennettNorth Carolina Harm Reduction Coalition, Wilmington, NC, USA.
Lauren KestnerQueen City Harm Reduction, Charlotte, NC, USA.
Christina S MeadeDepartment of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA.
Nidhi SachdevaDepartment of Population Health Sciences, Duke University School of Medicine, 215 Morris St, Durham, NC, 27701, USA.
Mehri S McKellarDepartment of Medicine, Duke University School of Medicine, Durham, NC, USA.

Funding

Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
NIAID NIH HHS P30 AI064518
6 · The paper itself

Abstract

backgroundPeople who inject drugs (PWID) are at risk for HIV and opioid overdose. We piloted PARTNER UP, a telemedicine-based program to provide PWID with access to both oral pre-exposure prophylaxis (PrEP) for HIV prevention and medication for opioid use disorder (MOUD) through two syringe services programs (SSPs) in North Carolina. We conducted a qualitative evaluation to assess the acceptability and feasibility of PARTNER UP from the participant perspective.

methodsPARTNER UP participants met with a provider for an initial in-person visit at the SSP, followed by weekly telemedicine visits in month 1 and then monthly telemedicine visits until program end at month 6. Using a qualitative descriptive study design, we conducted in-depth interviews with a subsample of PARTNER UP participants at 1 month and 4 months. Informed by the technology acceptance model, we assessed participant perceptions of the usefulness and ease of use of PARTNER UP, as well as their intent to continue to use the program's components. We audio-recorded all interviews with participants' permission and used applied thematic analysis to analyze the verbatim transcripts.

resultsWe interviewed 11 of 17 people who participated in PARTNER UP-10 in the month 1 interview and 8 in the month 4 interview. Nearly all participants were motivated to join for consistent and easy access to buprenorphine/naloxone (i.e., MOUD); only a few joined to access PrEP. Most were comfortable accessing healthcare at the SSP because of their relationship with and trust toward SSP staff, and accessing services at the SSP was preferred compared with other healthcare centers. Some participants described that telemedicine allowed them to be honest and share more information because the visits were not in-person and they chose the location, although the initial in-person meeting was helpful to build provider trust and rapport. Most participants found the visit schedule to be feasible, although half described needing to reschedule at least once. Nearly all participants who were interviewed intended to continue with MOUD after the program ended, whereas none were interested in continuing with PrEP.

conclusionsParticipant narratives suggest that the PARTNER UP telemedicine program was acceptable and feasible. Future studies should continue to explore the benefits of embedding both PrEP and MOUD into SSPs with larger numbers of participants. Trial registration Clinicaltrials.gov Identifier: NCT04521920.

Indexed as

HIV InfectionsOpioid-Related DisordersSubstance Abuse, IntravenousTelemedicineBuprenorphine, Naloxone Drug CombinationFeasibility StudiesHumansSyringesBuprenorphine, Naloxone Drug CombinationHIV preventionMedication for opioid use disorderPeople who inject drugsPre-exposure prophylaxisSyringe services programsTelemedicine

Identifiers

PMID36463214
PMCPMC9719634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.